Pharmaron Beijing Co., Ltd. (300759.SZ)
CNY 27.78
(-0.71%)
CNY 27.78
(-0.71%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 3.03 Billion CNY | 3.21% |
| 2022 | 2.63 Billion CNY | 0.66% |
| 2021 | 2.49 Billion CNY | 59.37% |
| 2020 | 1.8 Billion CNY | 59.05% |
| 2019 | 1.03 Billion CNY | 46.26% |
| 2018 | 700.55 Million CNY | 43.87% |
| 2017 | 486.93 Million CNY | 50.42% |
| 2016 | 324.86 Million CNY | 86.86% |
| 2015 | 149.11 Million CNY | 76.78% |
| 2014 | 92.73 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 450.19 Million CNY | -56.87% |
| 2024 Q1 | 366.77 Million CNY | -44.03% |
| 2024 Q2 | 644.09 Million CNY | 121.5% |
| 2023 FY | - CNY | 3.21% |
| 2023 Q3 | 421.08 Million CNY | -25.87% |
| 2023 Q2 | 568.04 Million CNY | 26.49% |
| 2023 Q1 | 449.07 Million CNY | -30.94% |
| 2023 Q4 | 662.39 Million CNY | 57.31% |
| 2022 Q1 | 311.63 Million CNY | -61.35% |
| 2022 Q3 | 404.26 Million CNY | -26.78% |
| 2022 Q4 | 650.22 Million CNY | 60.84% |
| 2022 FY | - CNY | 0.66% |
| 2022 Q2 | 552.08 Million CNY | 77.16% |
| 2021 Q3 | 530.15 Million CNY | 23.48% |
| 2021 Q4 | 806.24 Million CNY | 52.08% |
| 2021 Q1 | 333.62 Million CNY | -29.74% |
| 2021 FY | - CNY | 59.37% |
| 2021 Q2 | 429.33 Million CNY | 28.69% |
| 2020 Q3 | 312.29 Million CNY | -21.33% |
| 2020 Q2 | 396.97 Million CNY | 152.63% |
| 2020 Q1 | 157.13 Million CNY | -40.0% |
| 2020 FY | - CNY | 59.05% |
| 2020 Q4 | 474.81 Million CNY | 52.04% |
| 2019 Q4 | 261.88 Million CNY | 21.72% |
| 2019 Q3 | 215.15 Million CNY | 50.53% |
| 2019 Q2 | 142.93 Million CNY | 68.36% |
| 2019 Q1 | 84.89 Million CNY | -60.48% |
| 2019 FY | - CNY | 46.26% |
| 2018 Q4 | 214.8 Million CNY | 4.11% |
| 2018 FY | - CNY | 43.87% |
| 2018 Q3 | 206.33 Million CNY | 75.02% |
| 2018 Q2 | 117.88 Million CNY | 82.71% |
| 2018 Q1 | 64.52 Million CNY | -59.71% |
| 2017 Q4 | 160.15 Million CNY | 0.0% |
| 2017 FY | - CNY | 50.42% |
| 2016 FY | - CNY | 86.86% |
| 2015 FY | - CNY | 76.78% |
| 2014 FY | - CNY | 0.0% |